Liposomal vaccines incorporating molecular adjuvants and intrastructural T-cell help promote the immunogenicity of HIV membrane-proximal external region peptides.

An HIV vaccine capable of inducing high and durable levels of broadly neutralizing antibodies has thus far proven elusive. A promising antigen is the membrane-proximal external region (MPER) from gp41, a segment of the viral envelope recognized by a number of broadly neutralizing antibodies. Though an attractive vaccine target due to the linear nature of the epitope and its highly conserved sequence, MPER peptides are poorly immunogenic and may require display on membranes to achieve a physiological conformation matching the native virus. Here we systematically explored how the structure and composition of liposomes displaying MPER peptides impacts the strength and durability of humoral responses to this antigen as well as helper T-cell responses in mice. Administration of MPER peptides anchored to the surface of liposomes induced MPER-specific antibodies whereas MPER administered in oil-based emulsion adjuvants or alum did not, even when combined with Toll-like receptor agonists. High-titer IgG responses to liposomal MPER required the inclusion of molecular adjuvants such as monophosphoryl lipid A. Anti-MPER humoral responses were further enhanced by incorporating high-Tm lipids in the vesicle bilayer and optimizing the MPER density to a mean distance of ∼10-15 nm between peptides on the liposomes' surfaces. Encapsulation of helper epitopes within the vesicles allowed efficient "intrastructural" T-cell help, which promoted IgG responses to MPER while minimizing competing B-cell responses against the helper sequence. These results define several key properties of liposome formulations that promote durable, high-titer antibody responses against MPER peptides, which will be a prerequisite for a successful MPER-targeting vaccine.

[1]  H. Katinger,et al.  A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. , 2001, AIDS research and human retroviruses.

[2]  D. Montefiori,et al.  Rational Design of Membrane Proximal External Region Lipopeptides Containing Chemical Modifications for HIV-1 Vaccination , 2012, Clinical and Vaccine Immunology.

[3]  D. Baker,et al.  Elicitation of structure-specific antibodies by epitope scaffolds , 2010, Proceedings of the National Academy of Sciences.

[4]  S. Zolla-Pazner A critical question for HIV vaccine development: Which antibodies to induce? , 2014, Science.

[5]  C Leclerc,et al.  Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein. , 2000, Vaccine.

[6]  Robin A. Weiss,et al.  Neutralizing antibodies to HIV-1 induced by immunization , 2013, The Journal of experimental medicine.

[7]  J. Binley,et al.  An Affinity-Enhanced Neutralizing Antibody against the Membrane-Proximal External Region of Human Immunodeficiency Virus Type 1 gp41 Recognizes an Epitope between Those of 2F5 and 4E10 , 2007, Journal of Virology.

[8]  C. Guzmán,et al.  Cyclic di‐nucleotides: new era for small molecules as adjuvants , 2012, Microbial biotechnology.

[9]  F. Szoka,et al.  Role of lipid structure in the humoral immune response in mice to covalent lipid-peptides from the membrane proximal region of HIV-1 gp41. , 2009, Vaccine.

[10]  Jamie K. Scott,et al.  The Membrane-Proximal External Region of the Human Immunodeficiency Virus Type 1 Envelope: Dominant Site of Antibody Neutralization and Target for Vaccine Design , 2008, Microbiology and Molecular Biology Reviews.

[11]  J. Haensler,et al.  An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants , 2013, Expert review of vaccines.

[12]  J. Kappes,et al.  Neutralizing antibodies induced by liposomal HIV-1 glycoprotein 41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes , 2009, AIDS.

[13]  H. Liao,et al.  Induction of Antibodies in Rhesus Macaques That Recognize a Fusion-Intermediate Conformation of HIV-1 gp41 , 2011, PloS one.

[14]  E. Reinherz,et al.  Broadly neutralizing anti-HIV-1 antibodies disrupt a hinge-related function of gp41 at the membrane interface , 2009, Proceedings of the National Academy of Sciences.

[15]  K. Überla,et al.  Targeting Antibody Responses to the Membrane Proximal External Region of the Envelope Glycoprotein of Human Immunodeficiency Virus , 2012, PloS one.

[16]  L. Stamatatos,et al.  Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope. , 2010, Structure.

[17]  D. Burton,et al.  Antigenic and Immunogenic Study of Membrane-Proximal External Region-Grafted gp120 Antigens by a DNA Prime-Protein Boost Immunization Strategy , 2007, Journal of Virology.

[18]  D. Crommelin,et al.  Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. II. Influence of liposomal size, lipid compostion and lipid dose. , 1997, Biochimica et biophysica acta.

[19]  M. Bergeron,et al.  Sterically stabilized liposomes bearing anti-HLA-DR antibodies for targeting the primary cellular reservoirs of HIV-1. , 2000, Biochimica et biophysica acta.

[20]  M Juliana McElrath,et al.  Induction of immunity to human immunodeficiency virus type-1 by vaccination. , 2010, Immunity.

[21]  E. Reinherz,et al.  Antibody mechanics on a membrane-bound HIV segment essential for GP41-targeted viral neutralization , 2011, Nature Structural &Molecular Biology.

[22]  Critical issues in mucosal immunity for HIV-1 vaccine development. , 2008, The Journal of allergy and clinical immunology.

[23]  R. Cox,et al.  Intranasal c-di-GMP-adjuvanted plant-derived H5 influenza vaccine induces multifunctional Th1 CD4+ cells and strong mucosal and systemic antibody responses in mice. , 2011, Vaccine.

[24]  G Himmler,et al.  A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1 , 1993, Journal of virology.

[25]  B. Haynes,et al.  Modulation of Nonneutralizing HIV-1 gp41 Responses by an MHC-Restricted TH Epitope Overlapping Those of Membrane Proximal External Region Broadly Neutralizing Antibodies , 2014, The Journal of Immunology.

[26]  S. Moghimi,et al.  The effect of methoxy-PEG chain length and molecular architecture on lymph node targeting of immuno-PEG liposomes. , 2006, Biomaterials.

[27]  Leaf Huang,et al.  Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens. , 2012, Vaccine.

[28]  Peter D. Kwong,et al.  HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites , 2002, Nature.

[29]  Zhengrong Cui,et al.  Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses , 2010, Expert review of vaccines.

[30]  John A. Robinson,et al.  Engineered Synthetic Virus‐Like Particles and Their Use in Vaccine Delivery , 2011, Chembiochem : a European journal of chemical biology.

[31]  T. Yasuda,et al.  Effect of liposomal model membrane composition on immunogenicity. , 1978, Journal of immunology.

[32]  Jessica Yu,et al.  Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion state. , 2007, Vaccine.

[33]  Yanrong Wu,et al.  DNA-based micelles: synthesis, micellar properties and size-dependent cell permeability. , 2010, Chemistry.

[34]  D. Irvine,et al.  Immunogenicity of Membrane-bound HIV-1 gp41 Membrane-proximal External Region (MPER) Segments Is Dominated by Residue Accessibility and Modulated by Stereochemistry* , 2013, The Journal of Biological Chemistry.

[35]  Martin F. Bachmann,et al.  Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns , 2010, Nature Reviews Immunology.

[36]  G. Matyas,et al.  Liposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines , 2012, Expert review of vaccines.

[37]  Baoshan Zhang,et al.  Broad and potent neutralization of HIV-1 by a gp41-specific human antibody , 2012, Nature.

[38]  D. Leaman,et al.  Targeting HIV-1 gp41 in close proximity to the membrane using antibody and other molecules. , 2011, Current topics in medicinal chemistry.

[39]  Paul W. H. I. Parren,et al.  Broadly Neutralizing Antibodies Targeted to the Membrane-Proximal External Region of Human Immunodeficiency Virus Type 1 Glycoprotein gp41 , 2001, Journal of Virology.

[40]  N. K. Steede,et al.  Allocation of Helper T-cell Epitope Immunodominance According to Three-dimensional Structure in the Human Immunodeficiency Virus Type I Envelope Glycoprotein gp120* , 2001, The Journal of Biological Chemistry.

[41]  G. Kenner,et al.  Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: relating plasma circulation lifetimes to protein binding. , 2007, Biochimica et biophysica acta.

[42]  D. Gerlier,et al.  Enhancement of immunogenicity of tumour virus antigen by liposomes: the effect of lipid composition. , 1986, Immunology.

[43]  L. Lopalco,et al.  Virus like particle based strategy to elicit HIV-protective antibodies to the alpha-helic regions of gp41. , 2012, Virology.

[44]  M. Khan,et al.  Targeting to macrophages: role of physicochemical properties of particulate carriers--liposomes and microspheres--on the phagocytosis by macrophages. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[45]  Francisco A. Chaves,et al.  The kinetic stability of MHC class II:peptide complexes is a key parameter that dictates immunodominance. , 2005, Immunity.

[46]  C. Kao,et al.  Structure of STING bound to c-di-GMP Reveals the Mechanism of Cyclic Dinucleotide Recognition by the Immune System , 2012, Nature Structural &Molecular Biology.

[47]  H. Katinger,et al.  Characterization of a trimeric MPER containing HIV-1 gp41 antigen. , 2009, Virology.

[48]  V. Brusic,et al.  HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane. , 2008, Immunity.

[49]  Jason K. Pontrello,et al.  Activating B cell signaling with defined multivalent ligands. , 2007, ACS chemical biology.

[50]  David Baltimore,et al.  Antibody-based Protection Against HIV Infection by Vectored ImmunoProphylaxis , 2011, Nature.